Vertex Pays $4.9B for Kidney Disease Drug Developer
Working to move beyond its core business of cystic fibrosis treatments, Vertex recently gained approval for Casgevy, a gene editing therapy for sickle cell disease and beta thalassemia.
After clicking on a story, use the back arrow in your browser to return to your search results. Use phrases "in quotes" or the tools below to better filter your results.
